<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Hogarth</title>

    <link rel="preconnect" href="https://fonts.gstatic.com">
    <link href="https://fonts.googleapis.com/css2?family=Roboto:ital,wght@0,100;0,300;0,400;0,500;0,700;0,900;1,100;1,300;1,400;1,500;1,700;1,900&display=swap" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.3/css/all.min.css"
    rel="stylesheet" />
    <link rel="stylesheet" href="css/normalize.css">
    <link rel="stylesheet" href="style.css">
</head>

<body>
    <header>
        <img class="fondoRojo" src="images/fondo-vertical.jpg" alt="">
        <img class="headerBlanco" src="images/header-blanco-vertical.png" alt="">
        <a href=""><img class="icono" src="images/icono.png" alt=""></a>
        <a href=""><img class="logo" src="images/logo-vertical.png" alt=""></a>
    </header>

    <main>
        <div class="vaccine">
            <div>
                <img src="images/jeringas+vertical.png" alt="">
            </div>
            <div class="mainText">
                <p class="remind">
                    REMIND PATIENTS<br>TO COMPLETE THE<br>2-DOSE SERIES
                </p>
                <p class="the">
                    The second dose should be<br>administered2 to 6 months<br>after the first dose.
                </p>
            </div>
        </div>
        <div class="learn">
            <a class="learnMore" href="">LEARN MORE <i class="fas fa-caret-right"></i></a>
        </div>
        
        <a class="prescribing" href=""><u>PRESCRIBING INFORMATION </u><i class="fas fa-angle-right"></i></a>
    </main>

    <div class="scroll">
        <div class="scrollHere">
            <p>SCROLL HERE <i class="fas fa-caret-right"></i></p>
        </div>
        <p>
            <b>IMPORTANT SAFETY INFORMATION</b><br>
            •	SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX<br>
            •	Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX<br>
            •	Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)<br>
            •	Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)<br>
            •	SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion<br>
            •	Vaccination with SHINGRIX may not result in protection of all vaccine recipients<br>
            <br>
            <br>
            You are encouraged to report vaccine adverse events to the US Department of Health and Human Services. Visit <a href="">www.vaers.hhs.gov</a> to file a report, or call 1-800-822-7967.<br>
            <br>
            <br>
            This information is intended for US healthcare professionals only.<br>
            <br>
            <br>
            Trademarks owned or licensed by GSK<br>
            <br>
            <br>
            ©2018 GSK or licensor.<br>
            831155R0 October 2018
        </p>
    </div>

</body>
</html>